I think the market is yet to fully appreciate the significance...

I think the market is yet to fully appreciate the significance of the most recent results. Never before has RAP had verified double blind results and a clear path to commercialisation in Europe and Australia. Apart from being able to lodge this year for CE Mark they have an existing partnership with the German Hospital chain to roll the product out immediately upon approval.

Yes we are all waiting with baited breath to see the US results dues to the significance of FDA and size of the market, however RAP have now demonstrated that the product works. If for what ever reason the US results are not as strong as the Australian ones it will not be because the product doesn't work rather because they have again failed to understand the US Hospital system. It will mean a delay and another trial until they get it right and in the meantime they can pursue Europe.

Morgan's understand this which is why they have a price target of 35c. The rest of the market will catch up eventually.